<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00021164</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068756</org_study_id>
    <secondary_id>NCI-01-C-0176</secondary_id>
    <secondary_id>NCI-4970</secondary_id>
    <nct_id>NCT00021164</nct_id>
    <nct_alias>NCT00016640</nct_alias>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Metastatic Cancer</brief_title>
  <official_title>Immunization of HLA-A*0201 Patients With Metastatic Cancer Using a Peptide Epitope From the Telomerase Antigen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating&#xD;
      patients who have metastatic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether an immunologic response can be obtained in HLA*0201-expressing&#xD;
           patients with metastatic cancer treated with telomerase: 540-548 peptide vaccine&#xD;
           emulsified in Montanide ISA-51.&#xD;
&#xD;
        -  Determine which vaccine strategy (frequency, schedule, and dosing) is best for future&#xD;
           studies in these patients.&#xD;
&#xD;
        -  Determine the toxicity of this treatment in these patients.&#xD;
&#xD;
        -  Determine whether prior immunization with telomerase: 540-548 peptide vaccine results in&#xD;
           increased clinical response to interleukin-2 in patients with melanoma.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to disease (metastatic&#xD;
      cutaneous melanoma vs other tumor types). Patients are randomized to one of three treatment&#xD;
      arms.&#xD;
&#xD;
        -  Arm I: Patients receive telomerase: 540-548 peptide vaccine emulsified in Montanide&#xD;
           ISA-51 subcutaneously (SC) on day 1 of weeks 1-4 and 7-10. Patients also undergo&#xD;
           leukapheresis over 3 hours at baseline and after each course of treatment.&#xD;
&#xD;
        -  Arm II: Patients receive telomerase: 540-548 peptide vaccine emulsified in Montanide&#xD;
           ISA-51 SC on day 1 of weeks 1, 4, 7, and 10. Patients also undergo leukapheresis over 3&#xD;
           hours at baseline, after the vaccine on week 4, and after each course of treatment.&#xD;
&#xD;
        -  Arm III: Patients receive telomerase: 540-548 peptide vaccine emulsified in Montanide&#xD;
           ISA-51 SC on days 1-4 of weeks 1, 4, 7, and 10. Patients undergo leukapheresis as in arm&#xD;
           II.&#xD;
&#xD;
      Treatment in all arms repeats every 13 weeks for 4-6 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients with a complete response (CR) receive 1&#xD;
      additional course of treatment after achieving CR.&#xD;
&#xD;
      Eligible melanoma patients with progressive disease on vaccine alone on any of the 3 arms may&#xD;
      receive interleukin-2 (IL-2) combined with vaccine as in arm II. Beginning the day after each&#xD;
      immunization, IL-2 is administered IV over 15 minutes every 8 hours over 4 days on weeks 1,&#xD;
      4, 7, and 10 for a maximum of 12 doses. Patients continuing to experience disease progression&#xD;
      on combined vaccine and IL-2 therapy go off study after 2 courses of combined therapy.&#xD;
&#xD;
      Patients are followed at 3 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 90-162 patients (30-54 per treatment arm; 45-81 per stratum)&#xD;
      will be accrued for this study within less than 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2001</start_date>
  <completion_date type="Actual">May 2004</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Melanoma (Skin)</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>incomplete Freund's adjuvant</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>telomerase: 540-548 peptide vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Presenting with evaluable metastatic cancer&#xD;
&#xD;
               -  Refractory to standard treatment OR&#xD;
&#xD;
               -  Post-radiation for malignant glioma&#xD;
&#xD;
          -  HLA-A*0201 expression&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  16 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 90,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.6 mg/dL&#xD;
&#xD;
          -  AST/ALT less than 3 times normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No cardiac ischemia by stress thallium or comparable test*&#xD;
&#xD;
          -  No prior myocardial infarction*&#xD;
&#xD;
          -  No cardiac arrhythmias* NOTE: *Patients receiving interleukin-2 (IL-2) only&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No obstructive or restrictive pulmonary disease (patients receiving IL-2 only)&#xD;
&#xD;
        Immunologic:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No autoimmune disease or any other known immunodeficiency disease&#xD;
&#xD;
          -  No active primary or secondary immunodeficiency&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other active major medical illness*&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception NOTE: *Patients receiving IL-2 only&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior telomerase: 540-548 peptide immunization&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  Recovered from prior chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No requirement for systemic steroid therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 3 weeks since prior systemic therapy for cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven A. Rosenberg, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>NCI - Surgery Branch</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2004</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2013</last_update_posted>
  <keyword>stage IV melanoma</keyword>
  <keyword>recurrent melanoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Freund's Adjuvant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

